The T10 sequencing platform will provide a significant boost to Singapore’s sequencing power and enable ultra-high throughput multi-omics research including a transformational, high-resolution spatial-temporal transcriptomics pipeline powered by BGI-Research’s Stereo-seq technology. Different from the traditional sequencing slide and closed reaction system used in most platforms, T10 reimagined sequencing with a dip-immersion biochemistry method and open system to achieve the optimal balance among sequencing read length, throughput, data quality, and cost. T10 can produce up to 20TB data per day or equivalent of 200 whole human genomes sequenced at 30×. A single T10 system can produce about 50,000 WGS per year, which is eight to ten times of other sequencers in the market today.

Dr. Lihan ZHOU, Co-founder and CEO for MiRXES, said, “Since we started MiRXES in 2014, we have strived to develop disruptive technologies and innovative healthcare solutions that will change the way we manage diseases. We believe strongly that advances in genomics technologies will allow us, within this decade, to leapfrog a shift from treating the sick (often too late) to disease early detection to eventual prevention. The T10 sequencing platform, a key enabler to discover new biology and identify novel biomarkers for early detection of diseases and precision medicine, will help to develop and scale up preventive health solutions in Singapore and the region.”

Having APAC’s first T10 sequencing platform based in Singapore, an important hub for biomedical and clinical research, will enable the trio to forge collaborations with academic and clinical institutions and companies globally by giving access to cutting-edge capabilities to generate novel biological insights into complex diseases such as cancers, cardiovascular and neurological disorders, and allow for discovery of new biomarkers and pathways for targeted drug development.

Dr. Zhou added, “From conceptualization to designing and building the lab, and operationalizing the T10 sequencing platform, we took less than a year. This is a challenging achievement, and we deeply appreciate our like-minded partners MGI and BGI Research, for being with us on this journey. We look forward to what T10 and MiRXES, together with our partners, can do to accelerate preventive medicine and make genomic technologies accessible for all.”